Frontlight ResearchEarly access
Prostate cancer trials in Netherlands
55 of 69 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in NetherlandsA clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Maastricht, Nijmegen
- Age
- 18 years and over
- People
- 199 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-512340-32-01 - Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Amersfoort, Amsterdam, Heerlen, Hoofddorp, Leeuwarden, Nijmegen, Rotterdam, 's-Gravenhage, Tilburg, Venlo
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - Phase 1/2Not yet taking people in Netherlands[89Zr]Zr-PSMA-N139 PET/CT imaging in primary and recurrent prostate cancer.
- Where
- Nijmegen
- Age
- 18 years and over
- People
- 20
- Run by
- Radboud universitair medisch centrum Stichting
See details and how to join2025-523745-10-00 - Phase 1/2Taking peopleFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- Where
- Amsterdam, Nijmegen
- Age
- 18 years and over
- People
- 54 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07332455 - No phaseTaking peopleDose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 54
- Run by
- The Netherlands Cancer Institute
See details and how to joinNCT07391982 - Phase 3Taking peopleDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- Where
- Nijmegen
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584 - Phase 1Not yet taking people in NetherlandsA clinical trial of MK-1568 in participants with prostate cancer (MK-1568-001)
- Where
- Amsterdam, Nijmegen
- Age
- 18 years and over
- People
- 15
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2026-526983-19-00 - Phase 1WithdrawnA Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Where
- Rotterdam
- Age
- 18 years and over
- People
- 355 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06095089 · EU 2023-504063-17-00 - Phase 3Taking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Delft, Groningen, Hilversum, Hoofddorp, Maastricht, Nijmegen, Rotterdam, Zwolle
- Age
- 18 years and over
- People
- 1,203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - Phase 3Active, not recruitingA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Amsterdam, Leeuwarden, Nijmegen, Schiedam
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 3Taking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Almelo, Amersfoort, Amsterdam, Groningen, Hilversum, Hoofddorp, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, Venlo
- Age
- 18 years and over
- People
- 1,440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Amsterdam, Groningen, Leiden, Maastricht, Nijmegen
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Taking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Amsterdam
- Age
- 18 years to 100 years
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - Phase 2Taking peoplePan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
- Where
- Amsterdam
- Age
- 18 years and over
- People
- 153
- Run by
- Netherlands Cancer Institute
See details and how to joinNCT06279130 · EU 2023-505756-21-00 - Phase 3Taking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Groningen
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - Phase 3Not yet taking people in NetherlandsAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Amsterdam, Nijmegen
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - Phase 3Taking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Hilversum, Maastricht, Nijmegen, Roosendaal
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - Phase 3Active, not recruitingThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Amsterdam, Delft, Hilversum, Nijmegen
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - Phase 1/2Active, not recruitingA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Drachten, Ede Gld, Nijmegen
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - Phase 3Taking peoplePhase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Groningen
- Age
- 18 years and over
- People
- 297 worldwide
- Run by
- Amgen Inc.
See details and how to join2025-520555-89-00 - Phase 2Taking peopleDocetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
- Where
- Rotterdam
- Age
- 18 years and over
- People
- 245
- Run by
- Erasmus Medical Center
See details and how to joinNCT05762536 - Phase 3Taking people[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
- Where
- Nijmegen
- Age
- 18 years and over
- People
- 355 worldwide
- Run by
- Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
See details and how to join2023-504026-19-01 - Phase 1/2Not yet taking people in NetherlandsA Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Where
- Amsterdam, Maastricht
- Age
- 18 years and over
- People
- 52 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00 - Phase 3Not yet taking people in NetherlandsMultiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
- Where
- Amsterdam-Zuidoost
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Thomas Jefferson University
See details and how to joinNCT06024772 - Phase 1Taking peopleFirst-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Groningen, Rotterdam
- Age
- 18 years and over
- People
- 198 worldwide
- Run by
- Bayer
See details and how to joinNCT06217822 · EU 2023-507486-26-00